Start Date
December 31, 2017
Primary Completion Date
January 31, 2019
Study Completion Date
December 23, 2021
avelumab
Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
bevacizumab
Recombinant human anti-VEGF IgG1 monoclonal antibody
capecitabine
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
cyclophosphamide
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
5-Fluorouracil (5-FU)
5-fluoro-2,4 (1H,3H)-pyrimidinedione
leucovorin
Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
nab-paclitaxel
5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Lovaza
Omega-3-acid ethyl esters
Oxaliplatin
cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
rituximab
Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
Stereotactic Body Radiation Therapy
(SBRT)
ALT-803
recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-061
Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
haNK
NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY